acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
== Research == Vladimir Dilman first proposed in 1971 that biguanides like metformin and phenformin may have potential to treat cancer, prevent cancer, and to extend life, an idea that was subsequently supported by in vitro and animal studies, as well as an apparent reduction in the incidence of cancer in people taking metformin for diabetes. Laboratory studies attribute these apparent effects to inhibition of mTOR, inhibition of complex I, with phenformin being a more potent inhibitor than metformin, It appears that inhibition of complex I may cause diminished TCA cycle intermediate production and decreased mitochondrial ATP production thus resulting in AMPK activation and lower mTOR activity.
==== Codon models ==== Codon models describe the evolution of protein-coding nucleic acid sequences. The simplest codon model, MG, estimates one parameter: nonsynonymous/synonymous mutation ratio. The more complex GY also estimates transition/transversion rate ratios. Both of these are mechanistic models. They can be expanded by the addition of rate parameters. Empirical codon models directly describe the odds of one non-stop codon (61 in the standard code) being replaced by another, making them similar to amino acid exchangability matrices. By their construction, they are tied to the genetic code found in the data used to construct them. They can also be combined with a mechanistic model by multiplying the two estimated rates, adding back the ability to adapt to the data being processed.
== Detecting proteins == In some applications, it is necessary to measure the total amount of protein present, rather than the levels of one particular protein. In these cases nonspecific protein assays can be used to quantitate the amount of protein in a sample. Common nonspecific protein assays include the Warburg–Christian method, Kjeldahl method, Lowry assay, and Bradford assay. Many of these rely on the spectrophotometric properties of proteins themselves or in complex with various dyes or reagents. For example, the Bradford Assay exploits the absorbance properties of Coomassie brilliant blue G-250 dye. When free of protein, the dye is red but once bound to protein it turns blue. The Kjeldahl method, in contrast, does not use any dye and is instead a titrimetric assay, sensitive to the nitrogen content in the sample, which correlates with protein content. These assays vary widely in sensitivity, specificity to proteins over other compounds in the sample, and cost.
The old "Same Olds" nickname fell into disuse, and by 1922 the other nicknames "Sash Wearers" and "Essendonians" that had been variously used from time to time were also abandoned. The team became universally known as "the Dons" (from EssenDON). (The club adopted the nickname "the Bombers" at the start of 1940 during the early phases of World War II, due to Windy Hill's proximity to what was then Melbourne’s main airport, Essendon Aerodrome.) In the 1922 season, playing in Essendon for the first time in decades, Essendon reached the final four for the first time since 1912, finishing in third place. In the 1923 season, the club topped the ladder with 13 wins from 16 games. After a 17-point Second Semi-Final loss to South Melbourne, Essendon defeated Fitzroy (who had beaten South Melbourne) in the 1923 Grand Final (then known as a "Challenge Final" due to its different finals format): Essendon 8.15 (63) to Fitzroy 6.10 (46). Amongst Essendon's best players were half-forward flanker George "Tich" Shorten, centre half-forward Justin McCarthy, centre half-back Tom Fitzmaurice, rover Frank Maher, and wingman Jack Garden. This was one of Essendon's most famous sides, dubbed the "Mosquito Fleet" due to the number of small, very fast players in the side. Six players were 5'6" (167 cm) or shorter.
Sources: en.wikipedia.org
=== Greenlandic === The longest word in Greenlandic is Nalunaarasuartaateeraaranngualioqatigiiffissualioriataallaqqissupilorujussuanngortartuinnakasinngortinniamisaalinnguatsiaraluallaqqooqigaminngamiaasiinngooq, which has 156 letters. The rough translation of this word is: "There were reports that they apparently – God knows for how many times – once again had considered whatever I, my poor condition despite, still could be considered to be quite adept and resourceful as initiator to put a consortium together for the establishment of a range of tiny radio stations." The word is a tongue twister that forms an entire sentence, rather than being a word or phrase commonly heard in Greenland. Inuussutissarsiorsinnaajunnaarnersiutilik, consisting of 41 letters, is the longest singular word in the Greenlandic dictionary.
== In vitro test batteries == A method which could help decrease animal testing is the use of in vitro batteries, where several in vitro assays are compiled to cover multiple endpoints. Within developmental neurotoxicity and reproductive toxicity there are hopes for test batteries to become easy screening methods for prioritization for which chemicals to be risk assessed and in which order. Within ecotoxicology in vitro test batteries are already in use for regulatory purpose and for toxicological evaluation of chemicals. In vitro tests can also be combined with in vivo testing to make a in vitro in vivo test battery, for example for pharmaceutical testing.
Journal of Magnetic Resonance 19(1):114–117. 1978 With J. D. Stoesz and D. Malinowski. Cross relaxation and spin diffusion effects on the proton NMR of biopolymers in H₂O. Solvent saturation and chemical exchange in superoxide dismutase. FEBS Letters 91(2):320–324. 11 ALFRED REDFIELD 1979 With P. D. Johnston and N. Figueroa. Real-time solvent exchange studies of the imino and amino protons of yeast phenylalanine transfer RNA by Fourier transform NMR. Proceedings of the National Academy of Sciences U.S.A. 76(7):3130–3134. 1983 Stimulated echo NMR spectra and their use for heteronuclear two-dimensional shift correlation. Chemical Physics Letters 96(5):537–540. 1986 With M. A. Weiss and R. H. Griffey. Isotope-detected 1 H NMR studies of proteins: A general strategy for editing interproton nuclear Overhauser effects by heteronuclear decoupling, with application to phage λ repressor. Proceedings of the National Academy of Sciences, U.S.A. 83(5):1325–1329. 1987 With L. P. McIntosh, et al. Proton NMR measurements of bacteriophage T4 lysozyme aided by 15N isotopic labeling: Structural and dynamic studies of larger proteins. Proceedings of the National Academy of Sciences, U.S.A. 84(5):1244–1248. 1989 With S. C. Burk, M. Z. Papastavros, and F. McCormick. Identification of resonances from an oncogenic activating locus of human N-RAS-encoded p21 protein using isotope-edited NMR. Proceedings of the National Academy of Sciences, U.S.A. 86(3):817–820. 2009. With Shi, X. et al.
The first of these incursions occurred when a fleet of these Crusaders was invited by the Portuguese king Afonso I Henriques to conquer the city of Lisbon in 1142. Although this Siege of Lisbon (1142) was a failure it created a precedent for their involvement in Portugal. So in 1147 when another group of Norman and other groups of crusaders from Northern Europe arrived in Porto on their way to join the crusading forces of the Second Crusade, the Bishop of Porto and later Afonso Henriques according to De expugnatione Lyxbonensi convinced them to help with the siege of Lisbon. This time the city was captured and according to the arrangement agreed upon with the Portuguese monarch many of them settled in the newly sacked city. The following year the remainder of the crusading fleet, including a substantial number of Anglo-Normans, was invited by the count of Barcelona, Ramon Berenguer IV, to participate in the siege of Tortosa (1148). Again the Normans were rewarded with lands in the newly conquered frontier city.
The two opposing glutamates add and subtract protons from C1 and C2 and their respective oxygens, O1 and O2. The first half of the reaction transfers a proton from C1 to O2, whereas the second half transfers a proton from O1 to C2. The former reaction may be carried out by either of the opposing glutamates, depending on the initial chirality of C1 in the hemithioacetal substrate; however, the second half is stereospecific and is carried out by only one of the opposing glutamates. It is worthy to note that the first theoretically confirmed mechanism for the R-substrate of glyoxalase one published recently. The catalytic mechanism of Glyoxalase has been studied by density functional theory, molecular dynamics simulations and hybrid QM/MM methods. The reason for the special specificity of the enzyme (it accepts both enantiomers of its chiral substrate but converts them to the same enantiomer of the product) is the higher basicity and flexibility of one of the active site glutamates (Glu172).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.